Allergy Injections Side Effects: What Changes Across 60-80 Shots

Yes, for most patients side effects improve significantly over the course of treatment. Local reactions — redness, swelling, and itching at the injection site — tend to decrease in frequency and size after 6-12 months of consistent SCIT as immunologic tolerance develops. Systemic reaction risk drops substantially once patients reach and maintain the target maintenance dose: per AAAAI surveillance data, systemic reaction rates fall from approximately 0.2% per injection during build-up to about 0.05% during maintenance — a fourfold reduction. Patients who persist through the build-up phase typically find maintenance injections much more manageable. This improvement trajectory is one reason clinicians emphasize completing the full course rather than stopping when early reactions feel discouraging.

A standard SCIT course involves approximately 60-80 injections over 3-5 years. The build-up phase consists of weekly injections for 16-24 weeks (roughly 16-24 shots), with each visit delivering an incrementally higher allergen dose. Once the maintenance dose is reached, injections shift to monthly frequency for the remaining 3-4 years of treatment, adding approximately 36-48 maintenance injections. Some practices use cluster or rush build-up protocols that compress the build-up to 4-8 weeks but deliver multiple injections per visit. Each injection requires a 30-minute post-injection observation period, meaning the full treatment course represents 30-40 hours of observation time beyond the injections themselves — a meaningful logistical commitment that contributes to the 50-70% dropout rate before completion.

The highest systemic reaction risk in allergy shots occurs during the build-up phase — the first 3-6 months of dose escalation. According to AAAAI/ACAAI surveillance data encompassing over 54 million injection visits, approximately 70% of all systemic reactions occur during this escalation window. The per-injection systemic reaction rate during build-up is approximately 0.2%; it drops to about 0.05% during maintenance. Cluster and rush build-up schedules — which compress the timeline by delivering multiple injections per visit — carry roughly 3× the per-injection systemic reaction rate of conventional protocols. Even during maintenance, new vial transitions and injections during peak pollen season represent elevated-risk moments that warrant dose reduction and extended observation.

Long-term safety data on allergy injections are reassuring. The PAT Study followed patients for 10 years after treatment and found no new safety signals with prolonged SCIT. Cumulative aluminum adjuvant exposure over a 3-5 year course totals approximately 10-50 mg — comparable to dietary aluminum intake over the same period — and population-level studies have not demonstrated aluminum-related organ toxicity. Injection-site fibrosis and persistent subcutaneous nodules are possible with same-site repetition but are preventable with consistent site rotation. A Danish nationwide registry study (Linneberg 2012, JACI) found SCIT-treated patients had lower autoimmune disease risk, lower acute MI risk, and lower all-cause mortality compared to patients on conventional pharmacotherapy — a favorable long-term signal.

Treatment dropout affects 50-70% of SCIT patients before completing the recommended 3-5 year course, per Kiel et al. (JACI 2013). The primary drivers are injection fatigue — the cumulative burden of weekly then monthly clinic visits, each with mandatory 30-minute observation — combined with the practical demands of scheduling, travel, and lost time from work or childcare. Side effects, particularly during the more reactive build-up phase, also contribute to early discontinuation. Patients who drop out early typically lose their tolerance gains within 1-2 years. Incomplete treatment is arguably the largest clinical problem in allergy immunotherapy, and counseling patients about the side-effect arc — the improvement that comes after build-up — is an important strategy for supporting adherence.

Fatigue and malaise after allergy injections are described in patient reports and some clinical trial side-effect tables, but have not been rigorously quantified in dedicated studies — this is a genuine evidence gap noted in AAAAI surveillance commentary. The proposed mechanism is cytokine-mediated: allergen exposure triggers late-phase immune activation including release of IL-1, IL-6, and TNF-alpha, which are well-established mediators of fatigue and sickness behavior. Fatigue is more commonly reported during build-up or after dose escalations. Typical duration is hours to about 24 hours. Fatigue persisting beyond 48 hours, or accompanied by hives, wheezing, or other systemic symptoms, should be reported to the allergist as it may indicate a delayed systemic reaction rather than routine post-injection fatigue.

Based on available evidence, cumulative aluminum exposure from allergy shots over a 3-5 year course is considered safe. The total aluminum delivered across a full SCIT course — approximately 10-50 mg depending on the extract formulation — is comparable to dietary aluminum intake over the same period (Keith et al., Allergy Asthma Clin Immunol 2012). Population-level studies including the Linneberg 2012 Danish registry have not found adverse health outcomes linked to SCIT aluminum exposure. The primary documented local complication of aluminum-adsorbed extracts is subcutaneous granuloma formation when the same injection site is used repeatedly — not systemic toxicity. U.S. practice predominantly uses aqueous and glycerinated extracts rather than aluminum-adsorbed depot formulations, making nodule formation less common in American SCIT patients.